VaxNewMo’s Vaccine Breakthrough Published in Nature
EQ IQ- 2 Min Read
370 Views- Visitors
In order to offer transparency into how our stories are produced and to teach our readers about the importance of media literacy online, EQ's editorial team provides a quick self-rating of the integrity of the articles and the facts presented against the following EQ IQ metrics.
- Edited by EQ
- Submitted by BioSTL
- Inspired by VaxNewMo
- Suggested by Arch Grants
The BioGenerator-backed startup and Arch Grant recipient gets highlighted by Nature Communications for its 'promising process' to more quickly and affordably bring vaccines to market.
St. Louis bioscience startup VaxNewMo is developing broader and more affordable vaccines faster with its patented technology. The company’s breakthrough research is currently featured in Nature Magazine’s Communications section.
Publication in this major peer-reviewed journal validates VaxNewMo’s technology and highlights its findings in the article, “A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host.”
“VaxNewMo is developing more affordable pneumococcal conjugate vaccines that provide broader protection against more strains of bacteria that cause pneumococcal pneumonia,” said Dr. Mario Feldman, VaxNewMo Co-Founder and Associate Professor of Molecular Microbiology at Washington University School of Medicine in St. Louis.
“Additionally, our technology platform allows for a straightforward, more affordable method of developing other next-generation vaccines to protect against human and livestock infectious diseases.”
With its patented bioconjugation technology, VaxNewMo uses lab-safe E. coli to bypasses the dependency on the synthetic chemistry techniques previously required to manufacture conjugate vaccines. For its current study, VaxNewMo collaborated experiments with groups in Canada, Australia, and the U.S. VaxNewMo is a BioGenerator Labs tenant.
“We are proud to share our research and meet the high-quality threshold to be published in Nature Communications,” said Christian Harding, VaxNewMo CEO and Co-Founder.
“The St. Louis bioscience ecosystem has significantly propelled our research and development to reach this point. BioGenerator equipped us with funding and technical, business, and regulatory acumen, and Arch Grants also provided funding and pro bono support services.”
BioGenerator, the investment arm of BioSTL, has provided VaxNewMo with non-dilutive grant funding and business coaching for complex license negotiations, team building, and business strategy. Through its Grants-2-Business program, which coaches entrepreneurs through the process of submitting strong grant applications, BioGenerator has helped VaxNewMo win two federal grants totaling more than $500,000, as well as a $50,000 Arch Grant.
“VaxNewMo’s breakthrough approach to developing glycoconjugate vaccines holds out the promise of accelerating new and much more effective vaccines to market much faster than with traditional approaches,” said Harry Arader, Director of Entrepreneur Development at BioGenerator and VaxNewMo Business Coach.
“BioGenerator is proud to support Dr. Feldman and Dr. Harding to help them demonstrate that their technology will work and make a big difference protecting the most vulnerable among us.”